Case Reports in Endocrinology is a pioneering open access journal published by HINDAWI LTD, dedicated to advancing the field of endocrinology through the publication of case reports that illuminate the complexities of hormone-related disorders and metabolic issues. With its ISSN 2090-6501 and E-ISSN 2090-651X, the journal has been accessible since 2011, inviting contributions from researchers, clinicians, and students worldwide. Based in the United States, Case Reports in Endocrinology aims to disseminate critical insights and unique case analyses that contribute to the broader understanding of endocrinological conditions. While currently ranked Q4 in Endocrinology, Diabetes, and Metabolism, with Scopus placing it in the 29th percentile, the journal strives to enhance its impact and visibility. By fostering an environment for knowledge sharing and collaboration in a rapidly evolving field, this journal serves as an essential resource for those looking to deepen their understanding of endocrinological complexities and improve clinical practices.

Endocrine Metabolic & Immune Disorders-Drug Targets, published by Bentham Science Publishers, is a premier journal focused on the intricate interplay between endocrinology, metabolism, and immune response, with a particular emphasis on drug targets. Established in 2006 and set to continue its influence until 2024, this journal serves as a crucial platform for researchers and professionals to communicate significant advances in understanding metabolic and immune disorders, making it an invaluable resource in the realms of Endocrinology and Immunology. With an impact factor positioned within the Q3 category for both Endocrinology, Diabetes and Metabolism, and Immunology and Allergy as of 2023, the journal stands at the crossroads of critical research and clinical application, facilitating ongoing dialogue among the scientific community. Although currently not open access, its dedication to high-quality peer-reviewed articles ensures that cutting-edge research remains accessible to those invested in enhancing therapeutic strategies. For researchers and practitioners alike, Endocrine Metabolic & Immune Disorders-Drug Targets is an essential conduit for the latest findings that can influence treatment paradigms and bolster the understanding of complex biological systems.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

Journal of the Endocrine Society, published by the ENDOCRINE SOC, stands as a prominent platform for disseminating significant research and findings within the field of endocrinology, diabetes, and metabolism. Established as an Open Access journal since 2017, it aims to increase the visibility and accessibility of vital scholarly contributions, allowing researchers and professionals from various backgrounds to engage with the latest insights in this rapidly evolving discipline. With an impressive Q2 ranking in Endocrinology, Diabetes and Metabolism, the journal is recognized for its impact, ranking #100 out of 244 in Scopus, highlighting its role in advancing scientific knowledge and fostering innovation. The journal, based in the United States at 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036, continues to enrich the academic landscape by converging state-of-the-art research and clinical applications through its publication cycle from 2017 to 2024. Researchers, students, and healthcare professionals are encouraged to explore this essential resource to stay at the forefront of endocrinological advancements.

The International Journal of Endocrinology and Metabolism is a leading peer-reviewed publication dedicated to advancing knowledge and research in the fields of endocrinology, diabetes, and metabolism. Published by BRIEFLAND in the Netherlands, this journal features original research, comprehensive reviews, and insightful clinical studies that explore the multifaceted aspects of hormonal disorders and metabolic conditions. With an impact factor that places it in the Q3 quartile category for 2023, the journal serves as a critical resource for academics and practitioners aiming to stay at the forefront of this dynamic field. Spanning from 2010 to 2024, the journal offers an enriching platform for innovative ideas and practices, fostering collaboration among scholars and healthcare professionals alike. Although not open access, the content is meticulously curated to ensure high-quality scientific discourse, positioning the International Journal of Endocrinology and Metabolism as an essential reference for those dedicated to improving health outcomes related to endocrine and metabolic disorders.

Endocrine Practice is a premier journal dedicated to the dynamic and evolving field of endocrinology, published by Elsevier Inc.. With a significant emphasis on clinical practice, research, and advancements in the multidisciplinary domains of endocrinology, diabetes, and metabolism, this journal serves as a vital resource for researchers, healthcare professionals, and students alike. As a recognized leader in its field, it boasts an impressive impact factor and is ranked in the Q1 quartile for both Endocrinology and Medicine categories, reflecting its high-quality research contributions and relevance to contemporary clinical practice. The journal enjoys a robust reputation, achieving Scopus rankings with a placement of #57 out of 244 in Endocrinology, Diabetes and Metabolism, and #37 out of 128 in Biochemistry, Genetics and Molecular Biology. Although it is not available as open access, Endocrine Practice continues to disseminate critical findings from 2000 through to 2024, ensuring that professionals remain at the forefront of endocrine research and clinical application.

Nature Reviews Endocrinology is a premier journal published by NATURE PORTFOLIO, providing comprehensive and critical reviews in the rapidly evolving field of endocrinology. Established to foster advanced understanding, it has become a vital resource for researchers, professionals, and students alike. With an impressive impact factor and a prominent ranking of Q1 in both Endocrinology and Endocrinology, Diabetes, and Metabolism categories for 2023, the journal is recognized for its high-quality research dissemination, evidenced by its rankings of #2 out of 244 in Medicine and #2 out of 128 in Biochemistry, Genetics, and Molecular Biology. Spanning the years from 2009 to 2024, it focuses on publishing cutting-edge information that shapes current scientific knowledge and clinical practices. The journal offers open access options, ensuring greater visibility and reach for its articles. Located in Germany, this journal remains at the forefront of endocrinology research, significantly contributing to the understanding of hormonal functions and their implications on health. Discover the latest advancements and insights by exploring Nature Reviews Endocrinology.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Clinical Pediatric Endocrinology is a prestigious journal dedicated to advancing the field of pediatric endocrinology, published by the Japanese Society of Pediatric Endocrinology. With a respectable ISSN 0918-5739 and E-ISSN 1347-7358, this journal serves as a critical platform for innovative research spanning various aspects of endocrine disorders in children, including diabetes and metabolic conditions. Although it does not currently offer open access, it remains highly relevant in its category, being ranked in Q4 and Q3 tiers across multiple specialties as of 2023. With a publication history that spans from 1992 to 2024, this journal has contributed significantly to the literature, as evidenced by its inclusion in prominent databases. It invites submissions from researchers and practitioners worldwide, aiming to facilitate knowledge sharing and improve clinical practices in pediatric endocrinology. For those dedicated to enhancing care outcomes in children with endocrine disorders, Clinical Pediatric Endocrinology provides essential insights and fosters a community of engaged professionals.